This Project Grant award from the National Institute of Allergy and Infectious Diseases supports the development of a novel plant-based source for squalene as a natural vaccine adjuvant. The $514,006 award to Synshark LLC supports research to engineer tobacco plants to stably produce and accumulate squalene on their leaves. This work directly relates to the commercialization plan to provide a non-animal, indoor grown natural adjuvant for vaccines. Currently, squalene used in vaccines is...
This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program totaling $256,000 will develop Recombinant BCG as a novel immunoadjuvant for viral infections. The awardee, Oncosting LLC located in Baltimore, Maryland, will optimize media and lyophilization manufacturing of BCG-STING, evaluate its immunological effects as an adjuvant for H1N1 influenza vaccination, and assess its protective effects as an H1N1 vaccine adjuvant. By adding stimulator of...
This Project Grant from the National Science Foundation's Division of Chemical, Bioengineering, Environmental, and Transport Systems provides $500,000 to the Regents of the University of California at Riverside for research on rapid biomanufacturing of mRNA vaccines in plant chloroplasts. The award period is from January 1, 2022 to December 31, 2023. The research is funded under the NSF Directorate for Engineering's 47.041 CFDA program, which aims to improve quality of life and economic strength...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $2,521,615 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Regents of the University of California, Berkeley (UC Berkeley). The grant, which runs from July 2024 to May 2029, supports research to engineer adjuvants - biomolecules that enhance immune responses to vaccine antigens. Specifically, the project aims to redesign the microbial biosynthetic pathway for the adjuvant...
This Project Grant award, funded by the U.S. Department of Agriculture's (USDA) National Institute of Food and Agriculture under the Agriculture and Food Research Initiative (AFRI) program (CFDA 10.310), focuses on advancing knowledge and developing solutions to address disease and health management challenges in the growing U.S. aquaculture industry. The $649,995 award, spanning from September 1, 2024 to August 31, 2027, supports research to study the mechanisms of immune response and...
This Project Grant award of $709,236 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop a nanoparticle-based adjuvant formulation containing a TLR7 agonist to overcome immunodominance and induce broad antibody responses against the influenza virus. The primary research goals are to: 1) Determine how the TLR7 nanoparticle adjuvant impacts immunodominance, breadth, and tolerance across...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $390,942 to the Georgia TECH Research Corp to develop a universal influenza vaccine using self-assembled peptide nanoparticles (SAPNs). The goal is to present conserved influenza antigens, including the hemagglutinin stalk (HRHA) and matrix protein 2 ectodomain (4M2E), in a highly repetitive array on the SAPN...
This Project Grant award of $755,225.00, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a unique vaccine to prevent future pandemics caused by emerging coronavirus (CoV) strains. The goal is to design a mucosal CoV vaccine that targets conserved CoV antigens (S2, M, N) to induce protective T-cell responses, particularly tissue-resident memory T cells in the upper...
This Cooperative Agreement award from the U.S. Department of Agriculture's Animal and Plant Health Inspection Service (APHIS) under the Plant and Animal Disease, Pest Control, and Animal Care Federal Grant Program (CFDA 10.025) provides $238,731 to Oklahoma State University (OSU) from October 1, 2024 to September 30, 2026. The project aims to assess the efficacy of various vaccine adjuvants, including those equivalent to MF59 and AS03, compared to aluminum salts (alum) in eliciting humoral and...
This Project Grant award from the U.S. Department of Agriculture's (USDA) Agriculture and Food Research Initiative (AFRI) program, CFDA 10.310, provides $649,896 to the University of Illinois to develop an mRNA vaccine cocktail against influenza A viruses (IAV) that pose significant economic and pandemic threats to livestock and human populations. The vaccine candidate will combine mRNAs encoding a chimeric hemagglutinin (HA) protein with conserved HA stalk domains and an H5 antigen, delivered...